53 completed, 26 terminated, 3 withdrawn, 2 unknown. 52 Phase 2, 47 Phase 1, 2 Phase 3, 1 Phase 4.
Follow LBH589: new trials by email Literature Review of LBH589 trials Research Report on LBH589
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Carfilzomib, Chemosensitivity Assay, Dexamethasone - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 2 | Terminated | University of Washington | 9 | 2018-02-08 | 2022-05-09 |
| Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat Panobinostat, Carfilzomib, Lenalidomide - Multiple Myeloma | Phase 1 / Phase 2 | Withdrawn | H. Lee Moffitt Cancer Center and Research Institute | 2017-06-01 | 2017-04-25 | |
| Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma Dexamethasone, Panobinostat, Liposomal vincristine - Acute Lymphoblastic Leukemia, Lymphoma, Non-Hodgkin's | Phase 2 | Terminated | St. Jude Children's Research Hospital | 3 | 2016-11-23 | 2019-04-03 |
| A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat PDR001, LCL161, Everolimus - Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma | Phase 1 | Completed | Novartis Pharmaceuticals | 298 | 2016-10-14 | 2023-01-11 |
| Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma LBH589 - Glioma | Phase 1 | Completed | Pediatric Brain Tumor Consortium | 53 | 2016-06-28 | 2024-04-25 |
| Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT) Panobinostat - Multiple Myeloma | Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 30 | 2016-06-10 | 2022-11-01 |
| Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome Panobinostat, Fludarabine, Cytarabine - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Terminated | St. Jude Children's Research Hospital | 19 | 2016-05-03 | 2018-11-14 |
| Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy Panobinostat, Pegylated Interferon-alpha2a - HIV Infection | Phase 1 / Phase 2 | Completed | Massachusetts General Hospital | 17 | 2016-05-01 | 2024-02-28 |
| Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma Panobinostat Capsules, Bortezomib Injection, Dexamethasone tablets - Multiple Myeloma | Phase 2 | Completed | pharmaand GmbH | 248 | 2016-04-27 | 2024-07-12 |
| Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Gemcitabine Hydrochloride - Plasma Cell Leukemia, Plasmacytoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 83 | 2015-09-14 | 2025-03-18 |
| CINC424A2X01B Rollover Protocol ruxolitinib, panobinostat - Primary Myelofibrosis, Polycythemia Vera | Phase 4 | Active not recruiting | Novartis Pharmaceuticals | 279 | 2015-03-05 | 2026-10-19 |
| Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial) Panobinostat, Ruxolitinib - Myelofibrosis | Phase 1 / Phase 2 | Completed | John Mascarenhas | 15 | 2013-01-01 | 2023-10-31 |
| Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART Panobinostat - HIV Infection | Phase 1 / Phase 2 | Completed | University of Aarhus | 15 | 2012-09-01 | 2014-02-25 |
| A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients Panobinostat - Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) | Phase 1 | Completed | Novartis Pharmaceuticals | 10 | 2012-08-01 | 2020-12-19 |
| Panobinostat Biological Correlates Study panobinostat - Nodal Lymphoma, Lymphoma With Cutaneous Involvement | Phase 2 | Completed | Peter MacCallum Cancer Centre, Australia | 30 | 2012-07-16 | 2022-05-06 |
| Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM) Panobinostat, Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 2 | Completed | Ajai Chari | 32 | 2012-07-01 | 2018-04-09 |
| Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors Panobinostat, Stereotactic body radiation therapy, Quality-of-life assessment - Recurrent Glioma, High-grade Meningioma | Phase 1 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 17 | 2012-05-01 | 2025-05-02 |
| Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) RAD001, LBH589, Doublet (RAD001 and LBH589) - Diffuse Large B-cell Lymphoma | Phase 2 | Terminated | Anne Beaven, MD | 50 | 2012-02-01 | 2016-11-25 |
| Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome Panobinostat, Cytarabine, Daunorubicin - Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome | Phase 1 | Completed | University of California, San Francisco | 29 | 2012-01-01 | 2019-04-22 |
Showing 20 of 87. Sign in to see all of them.
Multiple Myeloma (19) · Recurrence (11) · Hodgkin Disease (8) · Leukemia, Myeloid, Acute (8) · Myelodysplastic Syndromes (8) · Lymphoma (7) · Lymphoma, Non-Hodgkin (7) · Neoplasms (7) · Lymphoma, Large B-Cell, Diffuse (6) · Primary Myelofibrosis (6) · Prostatic Neoplasms (6) · Leukemia (5) · Lymphoma, T-Cell, Cutaneous (5) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Breast Neoplasms (4)
Novartis Pharmaceuticals (31) · M.D. Anderson Cancer Center (4) · SCRI Development Innovations, LLC (4) · H. Lee Moffitt Cancer Center and Research Institute (3) · Dana-Farber Cancer Institute (2) · Emory University (2) · Massachusetts General Hospital (2) · Mayo Clinic (2) · Roswell Park Cancer Institute (2) · St. Jude Children's Research Hospital (2) · Abdullah Kutlar (1) · Ajai Chari (1) · Anand Jillella (1) · Anne Beaven, MD (1) · City of Hope Medical Center (1)
United States (71) · Germany (17) · Australia (10) · Canada (9) · Italy (9) · Spain (9) · Belgium (8) · France (8) · Japan (6) · Netherlands (6) · Sweden (6) · United Kingdom (5) · Brazil (4) · Israel (4) · Poland (4)
Abdullah Kutlar, MD (1) · Ajai Chari, MD (1) · Alessandro Levis, MD (1) · Anand Jillella, MD (1) · Andrew Cowan (1) · Anna Ferrari, MD (1) · Anne Traynor, M.D. (1) · Anne W. Beaven, MD (1) · Arkadiusz Dudek, MD (1) · Atae Utsunomiya (1) · Celeste Bello, M.D. (1) · Charalambos Andreadis, M.D. (1) · Daniel R Couriel, M.D. (1) · Daniel R Kuritzkes, MD (1)
PMID 25939707, PMID 39863139, PMID 21706316, PMID 21964801, PMID 21984064, PMID 22072492, PMID 22981498, PMID 23287861, PMID 23701016, PMID 23822537, PMID 23950178, PMID 24135804, PMID 25062770, PMID 25242045, PMID 25253045, PMID 25572329, PMID 26423811, PMID 26631116, PMID 26696749, PMID 27166360, PMID 27677481, PMID 27740633, PMID 27751707, PMID 28622959, PMID 28905323, PMID 29296798, PMID 30610196, PMID 30830886, PMID 31541945, PMID 31654285, PMID 31778911, PMID 32338562, PMID 33301738, PMID 34482353
2009 (5), 2005 (1), 2008 (1), 2014 (1), 2015 (1), 5UM1CA081457 (1), P30CA015083 (1), P30CA015704 (1), P30CA016672 (1), P30CA033572 (1)